Skip to main content
. 2022 Nov 2;13:1008755. doi: 10.3389/fphar.2022.1008755

TABLE 3.

Changes in liver function during neoadjuvant therapy cycles.

TBIL (μmol/L) DBIL (μmol/L) IBIL (μmol/L) ALT (U/L) AST (U/L) γ-GT (U/L) ALP (U/L) TB (g/L) ALB (g/L) GLB (g/L) AMY (U/L)
FC 14.6 7.6 7.0 50 16 22 59 67.9 40.5 27.4 69
SC 11.9 4.6 7.3 14 18 18 79 68.7 38.7 30 110
TC 19.4 8.4 11 21 31 22 101 70.1 39.2 30.9 106

FC, first circle; SC, second circle; TC, third circle.